Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
作者信息
Karim Salim S Abdool, Kashuba Angela D M, Werner Lise, Karim Quarraisha Abdool
机构信息
Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
出版信息
Lancet. 2011 Jul 16;378(9787):279-81. doi: 10.1016/S0140-6736(11)60878-7.
Abstract
摘要
相似文献
1
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Lancet. 2011 Jul 16;378(9787):279-81. doi: 10.1016/S0140-6736(11)60878-7.
2
Antiretrovirals for HIV prevention: translating promise into praxis.
Lancet. 2011 Jul 16;378(9787):206-8. doi: 10.1016/S0140-6736(11)61056-8.
3
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.
4
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
Antimicrob Agents Chemother. 2011 Oct;55(10):4905-7. doi: 10.1128/AAC.00120-11. Epub 2011 Jul 25.
5
Antiretroviral prophylaxis: a defining moment in HIV control.
Lancet. 2011 Dec 17;378(9809):e23-5. doi: 10.1016/S0140-6736(11)61136-7. Epub 2011 Jul 21.
6
Antiretroviral vaginal gel shows promise against HIV.
Lancet. 2010 Jul 31;376(9738):320. doi: 10.1016/s0140-6736(10)61123-3.
7
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
AIDS. 2007 Sep 12;21(14):1899-907. doi: 10.1097/QAD.0b013e328270385a.
8
FDA paves the way for pre-exposure HIV prophylaxis.
Lancet. 2012 Jul 28;380(9839):325. doi: 10.1016/s0140-6736(12)61235-5.
9
Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
JAMA. 2011 May 18;305(19):1952. doi: 10.1001/jama.2011.649.
10
AIDS: Drugs that prevent HIV infection.
Nature. 2011 Jan 20;469(7330):306-7. doi: 10.1038/469306a.
引用本文的文献
1
The Real-World Effectiveness of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Adults in Alberta, Canada: A Retrospective Population-Based Cohort Study.
Can J Infect Dis Med Microbiol. 2025 Aug 10;2025:9340622. doi: 10.1155/cjid/9340622. eCollection 2025.
2
Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.
NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):115. doi: 10.1038/s41522-025-00748-0.
3
Understanding the influence of the microbiome on childhood infections.
Expert Rev Anti Infect Ther. 2024 Jul;22(7):529-545. doi: 10.1080/14787210.2024.2340664. Epub 2024 Apr 12.
4
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.
J Int AIDS Soc. 2024 Mar;27(3):e26223. doi: 10.1002/jia2.26223.
5
Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01).
J Infect Dis. 2024 Apr 12;229(4):1131-1140. doi: 10.1093/infdis/jiad535.
6
How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.
J Int AIDS Soc. 2023 Nov;26(11):e26189. doi: 10.1002/jia2.26189.
7
Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy.
Biomaterials. 2023 Oct;301:122260. doi: 10.1016/j.biomaterials.2023.122260. Epub 2023 Aug 3.
8
Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.
Front Reprod Health. 2023 Jun 13;5:1118030. doi: 10.3389/frph.2023.1118030. eCollection 2023.
9
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Front Cell Infect Microbiol. 2023 Apr 19;13:1130101. doi: 10.3389/fcimb.2023.1130101. eCollection 2023.
10
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.
Front Immunol. 2022 Dec 6;13:1055042. doi: 10.3389/fimmu.2022.1055042. eCollection 2022.
本文引用的文献
1
Microbicides & their implications in HIV prevention.
Indian J Med Res. 2010 Dec;132(6):656-9.
2
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.
3
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19.
4
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
AIDS. 2007 Sep 12;21(14):1899-907. doi: 10.1097/QAD.0b013e328270385a.
Zotero 插件